Pharmacogenomics and clinical significance of rhabdomyosarcoma in children
10.3760/cma.j.issn.1673-422X.2018.12.013
- VernacularTitle:儿童横纹肌肉瘤常用化疗药物基因组学及其临床意义
- Author:
Xi CHAI
1
;
Xiaoli MA
Author Information
1. 国家儿童医学中心 首都医科大学附属北京儿童医院血液肿瘤中心 儿童血液病与肿瘤分子分型北京市重点实验室 儿科学国家重点学科 儿科重大疾病研究教育部重点实验室
- Keywords:
Rhabdomyosarcoma;
Pharmacogenetics;
Child
- From:
Journal of International Oncology
2018;45(12):760-764
- CountryChina
- Language:Chinese
-
Abstract:
Rhabdomyosarcoma is a common soft tissue malignant tumor in children.Multi-disciplinary combination therapy based on chemotherapy can improve the survival rate.Studies in chemotherapeutic pharmacogenomics indicate that the main cause of differences in individual drug responses is genetic polymorphism.Chemotherapy regimen include vincristine,actinomycin D,cyclophosphamide,irinotecan etc.CYP3A5 gene is related to neurotoxicity of vincristine,and ABCB1 gene is related to clearance rate of actinomycin D.CYP2C9 high expression makes increased hemorrhagic cystitis risk with cyclophosphamide.CYP2B6 is a predictor of neutrophil reduction in doxorubicin.UGT1A1 gene polymorphism is associated with severe diarrhea and neutropenia of irinotecan and CYP3A4 affects metabolism of etoposide.Detection of chemotherapeutic drug gene expression before treatment and adjustment of chemotherapy regimens can reduce adverse reactions and provide the possibility of individualized precision treatment.
